Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado Amalie K. Kropp Lopez, Stephanie D. Nichols, Daniel Y. Chung, Daniel E. Kaufman, Kenneth L. McCall and Brian J. Piper International Journal of Environmental Research and Public Health, 2020, 17, 3251 doi : 10.3390/ijerph17093251 Abstract : There have been dynamic changes in prescription opioid use in the US but the state level policy factors contributing to these are incompletely understood. We examined the association between the legalization of recreational marijuana and prescription opioid distribution in Colorado. Utah and Maryland, two states that had not legalized recreational marijuana, were selected for comparison. Prescription data reported to [...]
Lire la suiteAltered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004 Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]
Lire la suiteIn Search of Preventative Strategies: Novel Anti- Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues Bo Wang, Anna Kovalchuk, Dongping Li, Yaroslav Ilnytskyy, Igor Kovalchuk and Olga Kovalchuk Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 April 2020 doi : 10.20944/preprints202004.0315.v1 Abstract : With the rapidly growing pandemic of COVID-19 caused by the new and challenging to treat zoonotic SARS-CoV2 coronavirus, there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted [...]
Lire la suiteCannabinoids and the Coronavirus Kevin P. Hill Cannabis and Cannabinoid Research, 2020, Volume 5, Number 2, Doi : 10.1089/can.2020.0035 Introduction These are uncertain times as we attempt to manage our lives during the Coronavirus Covid-19 pandemic. It is not surprising, as possible treatments for Covid-19 are discussed, that people wonder about a role for cannabinoids, another topic associated with a lack of clarity about their therapeutic efficacy. Patients commonly ask clinicians about the benefits and risks of cannabinoids and now patients have begun to ask about cannabinoids as they relate to Covid-19. This interest creates an opportunity to strengthen the therapeutic alliance between patients and [...]
Lire la suiteRationale for cannabis-based interventions in the opioid overdose crisis Philippe Lucas Harm Reduction Journal, 2017, 14, 58 Doi : 10.1186/s12954-017-0183-9 Abstract Background : North America is currently in the grips of a crisis rooted in the use of licit and illicit opioid-based analgesics. Drug overdose is the leading cause of accidental death in Canada and the US, and the growing toll of opioid-related morbidity and mortality requires a diversity of novel therapeutic and harm reduction-based interventions. Research suggests that increasing adult access to both medical and recreational cannabis has significant positive impacts on public health and safety as a result of substitution effect. Observational and [...]
Lire la suiteCannabis Use Patterns and Motives: A Comparison of Younger, Middle-Aged, and Older Medical Cannabis Dispensary Patients Nancy A. Haug, Claudia B. Padula, James E. Sottile, Ryan Vandrey, Adrienne J. Heinz, and Marcel O. Bonn-Miller Addictive Behaviors, 2017, 72, 14-20. Doi : 10.1016/j.addbeh.2017.03.006 Abstract Introduction : Medical cannabis is increasingly being used for a variety of health conditions as more states implement legislation permitting medical use of cannabis. Little is known about medical cannabis use patterns and motives among adults across the lifespan. Methods : The present study examined data collected at a medical cannabis dispensary in San Francisco, California. Participants included 217 medical cannabis patients who [...]
Lire la suiteThe Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto and Lluis Ramió Frontiers in Neurology , 2020 | Volume 11 | Article 152 doi : 10.3389/fneur.2020.00152 Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic [...]
Lire la suiteCBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1 Lázaro García-Morales, Aída M Castillo, José Tapia Ramírez, Horacio Zamudio-Meza, Ma del Carmen Domínguez-Robles and Isaura Meza International Journal of Molecular Science, 2020, 21, 2429 doi : 10.3390/ijms21072429 Abstract : Cannabidiol (CBD) has been used to treat a variety of cancers and inflammatory conditions with controversial results. In previous work, we have shown that breast cancer MCF-7 cells, selected by their response to inflammatory IL-1 cytokine, acquire a malignant phenotype (6D cells) through an epithelial mesenchymal transition (EMT).We evaluated CBD as a potential inhibitor of this transition and inducer of [...]
Lire la suiteHigh Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn, Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095 Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]
Lire la suiteBenefits and adverse effects of cannabis use among adults with persistent pain Teresa Bigand, Cristina Lee Anderson, Mary Lee Roberts, Michele Rose Shaw, Marian Wilson Nursing Outlook, 2 0 1 9 , 67, 2 2 3 -2 3 1 doi : 10.1016/j.outlook.2018.12.014. A B S T R A C T Background : Increasingly, states are legalizing cannabis for recreational use. Improved accessibility may allow adults with pain to use cannabis more liberally. Greater understanding is needed about how adults with pain perceive the effects of cannabis, particularly those who also use opioid analgesics. Purpose : To examine the perceived effects of cannabis among adults who have [...]
Lire la suite